Status:
COMPLETED
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Lead Sponsor:
Gyeongsang National University Hospital
Collaborating Sponsors:
Dong-A University Hospital
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Eligibility Criteria
Inclusion
- Age older than 18
- Younger than 75
- ECOG performance status 0 or 1
- Histologically confirmed adenocarcinoma of the pancreas
- Metastatic pancreatic cancer
- No prior chemotherapy for metastatic pancreatic cancer
- A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)
Exclusion
- A patient with no measurable disease
- A patient who received previous palliative chemotherapy for pancreatic cancer
- A patient with locally advanced pancreatic cancer
- A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year
- A patient with previous active or passive immunotherapy
- A pregnant or lactating patient
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00922896
Start Date
June 1 2009
End Date
May 1 2011
Last Update
November 20 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dong-A University Hospital
Busan, South Korea, 602-715
2
Gyeongsang Unversity Hospital
Jinju, South Korea
3
Chung-Ang University Hospital
Seoul, South Korea, 156-755